Monza, Italy

Jörg Trappe

This inventor holds 2 USPTO granted patents. Top assignee: Bayer Aktiengesellschaft. Active years: 2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jörg Trappe. Retrieved from https://idiyas.com/inventor/jandoumlrg-trappe

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 50.0

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2002

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Mind of Jörg Trappe

Introduction

Jörg Trappe, a talented inventor based in Monza, Italy, has made significant contributions to the pharmaceutical field. With a total of two patents to his name, his work focuses on developing novel compounds with antiviral properties.

Latest Patents

One of Jörg Trappe's notable inventions is "Substituted indole sulfonamides as antiviral agents." This patent addresses novel compounds suitable for use as pharmaceuticals, detailing processes for their preparation and highlighting their effectiveness as antiviral agents. Another patent is related to "Naphthyl-substituted and anilide-substituted sulfonamides," further showcasing his dedication to advancing medication solutions.

Career Highlights

Jörg Trappe is associated with Bayer Aktiengesellschaft, a global leader in pharmaceuticals. His role at Bayer demonstrates his commitment to innovation within a company renowned for its focus on research and development in health.

Collaborations

Throughout his career, Jörg has collaborated with esteemed colleagues, including Wolfgang Bender and Jürgen Reefschläger. These collaborations underscore the importance of teamwork in his inventive process, contributing to the success of his innovations.

Conclusion

Jörg Trappe's work exemplifies the critical role of inventors in the advancement of science and medicine. With his innovative patents, he continues to push the boundaries of pharmaceutical development, significantly impacting how antiviral treatments are understood and utilized.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…